Image

Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081

Investigating the Effects of Immunotherapy in Unresectable Stage III Non-Small Cell Lung Cancer

Recruiting
18 years and older
All
Phase N/A
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates the effects of an investigational medication on patients with unresectable stage III non-small cell lung cancer (NSCLC). The purpose is to understand the benefits and side effects of using the investigational medication alone or in combination after patients have completed chemotherapy and radiation. NSCLC is a type of lung cancer that cannot be removed by surgery and has spread within the chest.

Participants will receive either the investigational medication alone or in combination. The study will monitor the effects of the treatment, which involves the body's immune system. This is called consolidation immunotherapy. Participants will be observed for any changes in their condition and any side effects they might experience.

  • Who can participate: Adults with unresectable or inoperable stage IIIA or IIIB non-small cell lung cancer who have completed prior cancer treatment at least 28 days before joining the study and have adequate organ function are eligible. Participants must not have active infections, metastatic disease, autoimmune diseases requiring treatment, and must not be pregnant or breastfeeding.
  • Study details: Participants will be randomly assigned to receive either the investigational medication alone or in combination with another. A placebo is not used in this study. Participants will be monitored for side effects and changes in their health.
Print
Study details
    NSCLC
    non-small cell lung cancer
    non small cell lung cancer
    non-small cell
    non small cell
    lung cancer
    lung
    lungs
    cancer
    oncology

TX8141

19 February 2024

Contact a study center
Step 1 Get in touch with the nearest study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact label
Please provide your preferred way of contact1234
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.